US equities
|
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Inozyme Pharma, Inc. - Common Stock
(NQ:
INZY
)
4.000
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Inozyme Pharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
This AutoNation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
September 12, 2024
Via
Benzinga
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
August 29, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
August 19, 2024
Via
Benzinga
Inozyme Pharma: Q4 Earnings Insights
↗
March 12, 2024
Via
Benzinga
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
↗
August 19, 2024
Via
Benzinga
INZY Stock Earnings: Inozyme Pharma Misses EPS for Q2 2024
↗
August 06, 2024
INZY stock results show that Inozyme Pharma missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
August 06, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
July 25, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
July 02, 2024
Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)
June 21, 2024
Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
May 30, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
May 23, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
May 08, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
INZY Stock Earnings: Inozyme Pharma Misses EPS for Q1 2024
↗
May 07, 2024
INZY stock results show that Inozyme Pharma missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 07, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
April 29, 2024
Via
Benzinga
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
April 09, 2024
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free
Via
Benzinga
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
April 08, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Top 5 Health Care Stocks That May Plunge In March
↗
March 28, 2024
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
March 26, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
March 12, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
February 26, 2024
- Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion -
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate in Upcoming Investor Conferences
November 09, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
November 07, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
